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the methylome of the celiac 
intestinal epithelium harbours 
genotype-independent alterations 
in the HLA region
Nora Fernandez-Jimenez1,2, Koldo Garcia-etxebarria2,5, Leticia plaza-Izurieta2, Irati Romero-
Garmendia2, Amaia Jauregi-Miguel2, Maria Legarda3, Szilvia ecsedi1,6, Ainara Castellanos-
Rubio2,4, Vincent Cahais1, Cyrille Cuenin1, Davide Degli Esposti  1,7, Iñaki Irastorza3, 
Hector Hernandez-Vargas  1,8, Zdenko Herceg1 & Jose Ramon Bilbao  2,4
the Human Leucocyte Antigen (HLA) locus and other DNA sequence variants identified in Genome-
Wide Association (GWA) studies explain around 50% of the heritability of celiac disease (CD). However, 
the pathogenesis of CD could be driven by other layers of genomic information independent from 
sequence variation, such as DNA methylation, and it is possible that allele-specific methylation explains 
part of the SNP associations. Since the DNA methylation landscape is expected to be different among 
cell types, we analyzed the methylome of the epithelial and immune cell populations of duodenal 
biopsies in CD patients and controls separately. We found a cell type-specific methylation signature that 
includes genes mapping to the HLA region, namely TAP1 and HLA-B. We also performed Immunochip 
SNP genotyping of the same samples and interrogated the expression of some of the affected genes. 
Our analysis revealed that the epithelial methylome is characterized by the loss of CpG island (CGI) 
boundaries, often associated to altered gene expression, and by the increased variability of the 
methylation across the samples. The overlap between differentially methylated positions (DMPs) and 
CD-associated SNPs or variants contributing to methylation quantitative trait loci (mQTLs) is minimal. 
In contrast, there is a notable enrichment of mQTLs among the most significant CD-associated SNPs. 
Our results support the notion that DNA methylation alterations constitute a genotype-independent 
event and confirm its role in the HLA region (apart from the well-known, DQ allele-specific effect). 
Finally, we find that a fraction of the CD-associated variants could exert its phenotypic effect through 
DNA methylation.
Celiac disease (CD [MIM 212750]) is a common, immune-mediated enteropathy that develops in genetically pre-
disposed individuals upon exposure to dietary gluten. HLA-DQ2 and HLA-DQ8 haplotypes account for around 
40% of the genetic contribution to CD and are present in virtually all celiac patients. The majority of efforts 
aimed at identifying the genetic predisposition to the disease have relied on SNP association studies, and the 
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contribution of common genetic variation identified so far, including HLA, amounts for roughly 50% of the herit-
ability1. However, other layers of genomic information that are independent from DNA sequence variation could 
also contribute to the pathogenesis of CD but have been left unscrutinized. In this sense, the identification of 
changes in DNA methylation that could have marked susceptible genomes in response to early-life environmental 
exposures, could help discover novel genomic regions involved in the onset and development of CD.
In the last decade, evidence has been accumulated suggesting that epigenetic makeup may represent an impor-
tant causal contributor to phenotypic variation and common diseases. For example, several immune diseases, 
including inflammatory bowel disease (IBD), type 1 diabetes (T1D) and different cancers, have been shown to 
harbour disease-specific genome-wide DNA methylation signatures2–4. However, there is growing criticism to the 
way this kind of studies have been carried out and recent publications strongly recommend (a) taking special care 
on cell type sorting, (b) controlling for genotype-effects on methylation profiles and (c) assesing the functional 
impact of the observed changes by transcription analyses5,6. Moreover, other approaches apart from the sole 
comparison of average methylation levels of single CpG positions in case/control studies should be implemented, 
such as accounting for the differential variation between groups to identify relevant methylation changes or field 
defects in the case of cancer6.
In CD, a previous candidate-gene methylation analysis in duodenal biopsies of patients was able to detect 
changes in the promoters of several NFkB-related genes7. However, one must consider that in the normal duo-
denum, the proportion of intraepithelial lymphocytes (IELs) does not exceed 5–10 IELs per 100 epithelial cells, 
while values in active CD mucosa largely exceed the pathological threshold of 20–25%8. These two cell com-
partments (epithelial and immune) are the two main fractions in the small intestinal mucosa and are expected 
to harbor different methylation profiles characteristic of each cell type. Analysis of DNA methylation in whole 
tissue will inevitably lead to misleading results because the different immune:epithelial cell type proportions in 
CD and control tissues will mask the disease-related changes in each cell group. For this reason, in this study we 
have performed a separate genome-wide methylation profiling in each of the two main cell populations from the 
duodenal mucosa.
There is also a growing interest in SNPs that may have influence on the methylation levels of nearby CpG sites, 
known as methylation Quantitative Trait Loci (mQTLs). It has been shown that the proportion of mQTLs was 
higher in the top associated SNPs from a bipolar disorder GWAS than in a random set of SNPs with comparable 
allele frequencies, and that those SNPs are located in microRNA binding sites9. More recently, the scrutiny of 
differentially methylated CpGs identified in schizophrenia patients revealed an enrichment for genes related to 
development and neurodifferentiation as well as an overrepresentation of GWAS risk loci10. Finally, allele-specific 
methylation has been reported in certain disease-associated SNPs, including CD, suggesting that DNA meth-
ylation could explain the phenotypic effects of at least some of the SNPs predisposing to CD11. Therefore, to be 
able to determine the scale at which differential DNA methylation is mediating SNP associations, it is impor-
tant to have dense SNP genotype data available from the same individuals where the methylome study has been 
performed.
The aim of the present study was to define the duodenal cell population-specific methylome of CD, to under-
stand its interaction with the CD-associated genetic variation and to explore the putative consequences of the 
identified methylation changes at the transcriptional level. Additionally, we aimed to ascertain whether a fraction 
of the genetic association in CD could be explained by allele-specific DNA methylation.
Methods
Subjects and samples. The study was approved by the Cruces University Hospital and Basque Clinical 
Trials and Ethics Committees (codes CEIC-E13/20 and PI2013072, respectively) and informed consent was 
obtained from all subjects or their parents. All experiments were performed in accordance with the relevant 
guidelines and regulations. CD was diagnosed according to the ESPGHAN (European Society of Pediatric 
Gastroenterology Hepatology and Nutrition) criteria in force at the time of recruitment, including anti-transglu-
taminase antibody (TGA) determinations as well as a confirmatory small bowel biopsy. Biopsy specimens from 
the distal duodenum were obtained during routine endoscopy from CD patients at the time of diagnosis (CD 
patients with clinically active disease, positive for autoantibodies againts tissue transglutaminase and presenting 
with atrophy of intestinal villi and crypt hyperplasia, who were on a non-restricted gluten-containing diet at that 
time), treated patients after at least two years on GFD (asymptomatic, autoantibody-negative and a normalized 
intestinal mucosa) and from non-celiac controls that underwent endoscopy for causes other than inflammation 
(Table S1). The complete biopsies used for biological validation were snap-frozen and stored in liquid nitrogen 
until nucleic acid extraction. Those biopsies from which immune and epithelial cell populations were sorted, were 
processed immediately as described below. Biopsies from cases and controls were stored in the same way for each 
of the experiments and all comparisons were performed between samples treated in the same way.
Sample processing, cell separation and purification of nucleic acids. Enterocytes and immune cells 
are the principal cell populations of the duodenal mucosa. The former express the epithelial cell adhesion mole-
cule EpCAM (CD326) on their surface, while leukocytes harbor the CD45 antigen encoded by the PTPRC gene. 
These characteristics make it possible to separate and distinguish both cell populations from a biopsy sample, 
and allow the independent study of both cell types in CD. For that purpose, MACS magnetic cell separation 
technology was used (except when otherwise stated, all components from Miltenyi Biotec, Bergisch Gladbach, 
Germany), following the manufacturer’s protocol. Briefly, cells were mechanically separated from fresh biopsies 
by rotation-agitation in 10 ml of RPMI medium supplemented with 2% FBS, 1% DTT and 5 nM EDTA for 1 hour. 
The lamina propria and debris were removed by filtration through 30 µm pre-separation filters (cat. no. 130-
041-407) and dead cell removal kit (cat. no. 130-090-101) was used to prepare a viable single-cell homogenous 
suspension. Live cells were labelled with CD45 magnetic microbeads (cat. no. 130-045-801) in the presence of 
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FcR blocking reagent (cat. no. 130-059-901) to increase the specificity of antibody labelling. The antibody-labelled 
cell-suspension was applied to a magnetic separation column (cat. no. 130-042-201) and unlabelled CD45- cells 
(mainly the epithelial CD326+ fraction) were collected with the flow-through, while CD45+ cells were recovered 
after removing the column from the magnet.
Both cell fractions and the lamina propria were stored in RLT lysis buffer (Qiagen, Hilden, Germany) at 
−80 °C until nucleic acid extraction. RNA and DNA from all biological samples were isolated using the AllPrep 
DNA/RNA micro kit (Qiagen, cat. no. 80284) following the manufacturer´s instructions, and stored at −80 °C 
until use. DNA and RNA were quantified by fluorometry using the Qubit dsDNA-HS and RNA-HS assays 
(Thermo Scientific, Waltham, MA, cat. nos. Q32854 and Q32855, respectively) and the quality of the RNA was 
evaluated by electrophoresis on Agilent RNA Nano Chips (Agilent Technologies, cat. no. 5067-1511).
The extraction of both DNA and RNA from the same samples was very challenging and in many cases, it was 
not possible to fulfill the minimum amount or quality standards required by the genome-wide techniques applied 
in the present study. Thus, we could not obtain all the information from all patients and although DNA methyla-
tion and SNP genotypes are available for the same individuals, RNAseq analysis has been performed in a partially 
different patient cohort (Table S1).
Genome-wide methylation analysis. DNA from 20 epithelial fractions and 20 immune fractions (sepa-
rated from duodenal biopsies from 10 CD patients and 10 controls) was bisulfite converted, and bisulfite-treated 
DNA samples were subjected to the Illumina Infinium HumanMethylation450 microarray analysis, essentially as 
described previously12. The main particularity of this part of the study was the fact that, for the first time in our 
laboratory, we used only 100 ng of DNA per sample, due to the limited nucleic acid availability after cell sorting.
After Infinium bead array recommended preparation and scanning13, raw methylation data were imported and 
processed using R/Bioconductor packages, including Lumi, wateRmelon and minfi14–16. In particular, data quality 
was inspected using boxplots for the distribution of methylated and unmethylated signals, and inter-sample rela-
tionship using multidimensional scaling plots and unsupervised clustering. Probes were filtered for low quality 
with the pfilter function15, and the three samples with a detection P value > 0.05 in >5% of the sites were removed 
(Table S1). Additionally, known cross-reactive probes17 were also excluded from further analysis. The remaining 
dataset was background-subtracted, and normalized using intra-array beta-mixture quantile normalization18.
Methylation beta values were logarithmically transformed to M values before parametric statistical analyses, 
as recommended19. To define differentially methylated positions (DMPs) and differentially methylated regions 
(DMRs), we modelled the main variables as a categorical variable (i.e. control vs. disease, cell subtype) in a lin-
ear regression using the limma package, an empirical Bayesian approach20,21. DMPs and DMRs were selected 
based on a FDR-adjusted p value < 0.05. DMRs were identified with the DMRcate package using the recom-
mended proximity-based criteria22. In addition, a DMR was defined by the presence of at least 2 differentially 
methylated CpG sites with a maximum gap of 1000 bp. Functional pathway enrichment was performed with the 
Enrichr web application23. In addition, the package coMET was used for visualisation of regional associations and 
co-methylation patterns24. Differentially variable and methylated CpG sites (DVMCs) were identified using the 
iEVORA algorithm with the recommended parameters of adjusted and non-adjusted p values25.
Direct bisulfite sequencing. In this technique, primers are designed to be strand-specific as well as 
bisulfite-specific, flanking (but not involving) the CpGs of interest. Thus, both methylated and unmethylated 
sequences will be amplified, in contrast to methylation-specific PCR. All unmethylated cytosines will be displayed 
as thymines in the resulting amplicon of the sense strand, and as adenines in the amplified antisense strand. This 
technique requires amplification of the target region by PCR prior to sequencing for adequate sensitivity. Here, 
we used this technique to confirm the differential methylation of the DMRs mapping to the TAP1 and the HLA-B 
promoter in an independent cohort of complete biopsies coming from 7 GFD-treated CD patients and 7 controls.
In particular, we used the following primers to amplify 6 CpGs per gene within each previously 
defined DMR after bisufite conversion: TAGGGAATAGATTGAAGGTTTTAGG (forward strand) and 
CAATCTAACTAAAACTAACCTACTTAAACT (reverse strand), and AAATTTTTAGTGGGATAAGAAAAT 
(forward strand) and CCAAAAATAAACAACTATAATAATACCTTC (reverse strand) for TAP1 and HLA-B, 
respectively, using the PyroMark PCR Kit (Qiagen, cat. no. 978703 VF 40). Afterwards, NucleoSpin Gel and PCR 
Clean-up (Macherey-Nagel, Düren, Germany, cat. no. 740609.250) were used to purify the pooled amplicons of 
each individuals. Libraries were generated with a Nextera XT kit (Illumina, cat. no. FC-131-1024) and these were 
sequenced in an Illumina MiSeq system by using the Miseq Reagent kit v3 (600 cycles, 25 M reads) (Illumina, cat. 
no. MS-102-300).
Genotyping. The HumanImmuno v1.0 BeadChip (Illumina Inc., San Diego, CA) was used for genotyping 
DNA extracted from the lamina propria of the same patients in which the methylome study was carried out (10 
CD and 10 controls) at the CIC Biogune Genomics Platform, Derio-Bizkaia, Spain, according to Illumina proto-
cols. SNP mapping and allele calling were done essentially as described in the original Immunochip article1. To 
search for interactions between SNPs and methylation levels we adapted the Matrix eQTL package and checked 
the correlations within 5 Kb upstream and downstream of each of the polymorphisms (FDR-corrected p < 0.05)26.
Transcriptome analysis. Total RNAseq was performed in (a) 22 epithelial fractions of biopsies taken 
from 10 CD patients and 12 control individuals without intestinal inflammation at the time of endoscopy; 
(b) 12 immune fractions of biopsies taken from 7 celiac and 5 control individuals, and (c) 8 complete biopsies 
taken from 4 celiac and 4 control individuals at the CIC Biogune Genomics Platform and the Beijing Genomics 
Institute.
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Libraries were prepared using the TruSeq Stranded Total RNA kit (Illumina Inc., cat. no. RS-122- 2201), fol-
lowing the TruSeq® Stranded Total RNA Sample Preparation Guide. Starting from 50 ng of total RNA, Eukaryotic 
rRNA was depleted and remaining RNA was purified, fragmented and primed for cDNA synthesis. cDNA first 
strand was synthesized with SuperScript-II Reverse Transcriptase (Life Technologies, cat. no. 18064–014) for 
10 min at 25 °C, 15 min at 42 °C, 15 min at 72 °C. Second strand cDNA was synthesized with Illumina reagents 
at 16 °C for 1 hour. Then, A-tailing and adaptor ligation were performed. Finally, enrichment of libraries was 
achieved by PCR (30 sec at 98 °C; 15 cycles of 10 sec at 98 °C, 30 sec at 60 °C, 30 sec at 72 °C; 5 min at 72 °C).
On the other hand, libraries were visualized on an Agilent 2100 Bioanalyzer using Agilent High Sensitivity 
DNA kit (Agilent Technologies, cat. no. G2938-90320) and quantified using quantitative PCR with Kappa Library 
Quantification Kit (Master Mix and DNA Standards, KAPA – Biosystems cat. no. KK4824) and Qubit dsDNA 
HS DNA Kit (Life Technologies, cat. no. 32851). Paired-end sequencing of 75 nucleotides was carried out in a 
HiScanSQ platform (Illumina Inc.). Libraries were pooled and each pool sequenced in two lanes at a final con-
centration of 3.7 pM (each library was intended to be sequenced at 0.458 pM per lane). On average we generated 
30 +/− 2.5 (mean +/− SD) million reads per sample.
Sickle was used to remove low quality reads, -n 13 option was used and the rest of options set to the default 
values27. The Tuxedo protocol was used to map sequenced reads against the human reference genome (Hg38) 
with Tophat and providing GENCODE 24 as reference transcriptome28,29. Cufflinks was used to assemble the 
transcriptome using de novo transcript search and to calculate the FPKM value of each transcript, to test the 
differences between health and disease, and to get the normalized values30. Additionally, DESeq2 and edgeR were 
used to detect differential expression related to CD (FDR < 0.02) in the form of normalized counts31,32. In both 
cases, we used the number of raw counts calculated by Cufflinks. In the case of edgeR “quasi likelihood” analysis 
was used. We considered a particular gene to be expressed when raw counts >5 in more than the 50% of the 
samples.
Results
Separation of the epithelial and the immune cellular fractions from intestinal biopsies. Taking 
advantage of the fact that epithelial cells express the epithelial cell adhesion molecule EpCAM (CD326) on their 
surface33 while immune cells harbor the CD45 antigen encoded by the PTPRC gene34, we developed a rapid 
procedure for the separation of the two cell populations from duodenal biopsy samples in order to perform inde-
pendent DNA methylation studies in each of them. It is important to bear in mind the difficulty to obtain enough 
DNA from both cell fractions.
In this context, the relative expression of EPCAM and PTPRC was used to account for the efficiency of the cell 
separation through the estimation of the proportion of the epithelial cells and the intraepithelial lymphocytes 
(IELs), respectively. More specifically, we took into consideration the normalized counts of these two genes in 
our RNAseq study. The purity of the epithelial fraction (expressed as EPCAM:PTPRC) was 99 ± 1% (Fig. 1), while 
the average purity of the immune fraction (PTPRC:EPCAM ratio) was 90 ± 7%. It is important to stress that 
there were no significant differences in the enrichment for the immune cellular fraction between control and CD 
samples after separation, reducing the DNA methylation bias that the different IEL proportion in whole tissues 
would generate.
Figure 1. The efficiency estimation of the cell separation. The relative expression (normalized RNAseq counts) 
of EPCAM and PTPRC was used to account for the efficiency of the cell separation through the estimation of the 
proportion of the epithelial cells and the IELs, respectively. The purity of the epithelial and the immune fraction 
(expressed as EPCAM:PTPRC and PTPRC:EPCAM) was 99 ± 1% and 90 ± 7%, respectively.
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Differentially methylated positions in epithelial and immune cell fractions of the celiac duode-
nal mucosa. To investigate the methylation profile in CD, we analyzed 40 DNA methylomes from 10 control 
individuals without intestinal inflammation when endoscopy was performed and 10 CD patients at diagnosis. 
DNA for methylation analyses was extracted from both the epithelial and the immune cell compartments from all 
the individuals in the study. The association tests for disease status in the form of a Q-Q plot (Fig. S1) showed a 
lambda factor of 1.2 and therefore, a minimal inflation of the results.
Comparison between CD patients and controls identified 43 differentially methylated positions (DMPs) (11 
hypo and 32 hypermethylated) and 310 DMPs (40 hypo and 270 hypermethylated) in the epithelial and immune 
fractions, respectively, using FDR <0.05 and delta-beta >10% as thresholds (Table S2). In the epithelial compart-
ment, 18 hits with delta-beta >20% and located in close proximity to 15 different genes, were able to perfectly 
discriminate CD and control samples (Fig. 2A). We also observed that the hypomethylated positions seemed to 
be more abundant in promoter and transcription start site (TSS) proximal regions, with a slight decrease of CpG 
islands (CGI) (Fig. 2B,C), but these results were not significant. The most represented pathways among the dif-
ferentially methylated hits were type 1 diabetes and adhesion molecules (FDR < 0.05) (Fig. 2D), coherent with our 
prior knowledge on the disease.
On the other hand, in the immune compartment, 26 hits with delta-beta >20% and located close to 25 differ-
ent genes, were able to unambiguously cluster CD and control samples (Fig. 2A). The analysis of the immune cell 
DMP set showed a significant decrease of CGI (χ2 > 7.950, p = 0.0048 and χ2 > 31.489, p < 0.00001 for hypo and 
hypermethylated DMPs, respectively) together with an enrichment of open sea regions (χ2 > 3.411, p = 0.0648 
and χ2 > 8.948, p = 0.0028 for hypo and hypermethylated DMPs, respectively) (Fig. 2B,C). Interestingly, apoptosis 
was the main enriched pathway in the genes close to the immune cell-specific DMPs (FDR < 0.05) (Fig. 2D).
RNAseq results from epithelial fractions from 10 CD patients and 12 controls, and immune fractions from 7 
patients and 5 controls (Table S3) showed that 11/15 and all 25 differentially methylated genes were expressed in 
the epithelial and immune cell compartments, respectively. Seven of the eleven genes expressed in the epithelial 
fraction (HLA-DPB1, TAP1, PSMB9, HLA-DPA1 and HLA-B in the HLA region on chromosome 6, and SDR42E1 
and NLRC5, located elsewhere) were differentially expressed in CD (Fig. S2). Four out of those seven genes (TAP1 
and PSMB9 in the HLA, and SDR42E1 and NLRC5) were also differentially expressed in the immune fraction. In 
contrast, out of the 25 genes close to the immune DMPs only IL15RA and ZFAT were overexpressed, in both cell 
populations.
Figure 2. General DMP analysis for CD status in each cell type. (A) Heatmap showing active CD (black) and 
controls (grey) in columns and the genes closest to the most differentially methylated DMPs in rows, with the 
blue-red color scale representing the hypo- to hypermethylation trend. (B,C) Distribution of DMPs, relative 
to transcription start sites, genomic features and CpG content and characterization, respectively. (D) KEGG 
pathway analysis of the DMPs. All analyses were performed with FDR < 0.05 and delta-beta > 10% cuttoffs, 
except for the heatmap (delta-beta > 20%).
www.nature.com/scientificreports/
6Scientific RepoRts |          (2019) 9:1298  | https://doi.org/10.1038/s41598-018-37746-6
Differentially variable and methylated CpG sites in epithelial and immune cell fractions of the 
celiac duodenal mucosa. Increased variation in DNA methylation has been proposed as a characteristic 
of certain conditions, including premalignant stages35. We identified 560 differentially variable and differentially 
methylated CpGs (DVMCs) associated to CD in the epithelial cell population, out of which 93.6% were more 
variable in the disease group, and were borderline significant for the IBD pathway (FDR = 0.05798). In turn, 
there were 851 celiac-associated DVMCs in the immune cells, but only 26% were more variable in CD, and 
were not enriched in any particular term (Table S4, Fig. 3). According to the RNAseq results, four of the genes 
Figure 3. Most variably and differentially methylated positions in each cell type. The figure shows the top 
DVMCs per cell fraction, according to the iEVORA R package, as described in Methods. Grey and black circles 
represent control and celiac samples, respectively.
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that were close to the six most significant DVMCs of the epithelial fraction were differentially expressed in CD; 
namely NEDD1, PSMB9, PKLR and HLA-DPA1. In general, DVMCs seemed to be related to fewer changes in 
gene expression in the case of the immune fraction (Table S3, Fig. S3).
Cell population-specific differentially methylated regions in celiac disease. Since DNA meth-
ylation of neighbouring CpG sites can be highly correlated, we applied dimension reduction to search for CpG 
clusters that define differentially methylated regions (DMRs) (Table S5). We found six DMRs in epithelial cells, 
while 100 were significant in the immune cell compartment (only significant DMPs were taken into consideration 
for DMR identification). Taking into account the strong linkage disequilibrium in the HLA region, we classified 
DMRs into those on that region of chromosome 6 and those located elsewhere in the genome. Four epithelial 
and 7 immune DMRs were located in the HLA region, and two of them (TAP1 and TRIM15) were common to 
both cell populations. The limited overlap between the two cell populations supports the idea that disease-related 
differences in DNA methylation present only in one of the cell types, could be genotype-independent, cell 
type-specific epigenetic marks that respond to the environmental component of the disease.
One of the most significant HLA-DMRs in the epithelial compartment mapped to TAP1, and consisted of 
two small regions surrounding a CGI in its gene promoter that were significantly hypomethylated in epithelial 
cells from CD patients, and showed a weaker trend in immune cells (Fig. 4). The hypomethylated region also 
overlapped with an intron of PSMB9. Additionally, comethylation was much stronger in epithelial cells compared 
to their immune counterparts, suggesting a higher degree of coordination in the former. In the case of HLA-B, 
with a DMR exclusive for the epithelial fraction, we also found a significantly hypomethylated CGI shore in its 
promoter region (Fig. S4). Interestingly, the XXbac-BPG248L24.12 pseudogene overlapped the most CpG-dense 
locus of the surroundings. On the other hand, the top non-HLA DMRs in celiac disease mapped to genes related 
to the immune response, including NLRC5 and TMEM105 in the epithelial fraction, and CAST and HOXC4 in 
the immune compartment (Fig. S5).
From a structural point of view, the most significant DMRs exhibited loss of CGI boundaries, or the blurring 
of the demarcated borders between high and low methylated regions defined by CGIs, a feature that has been 
described in cancer36. In general, boundary shifts into CGIs appear as hypermethylated islands while boundary 
shifts outside the islands appear as hypomethylated shores37,38. The former is observed in CAST and HOXC4 and, 
to a lesser extent, in TMEM105, since significant hypermethylation is found in the most CpG-dense region of the 
surrounding genomic landscape (10 Kb). On the contrary, CGI shores are hypomethylated in the rest of the top 
DMRs, particularly HLA-B, NLRC5 and TAP1.
Validation of the differential methylation of the TAP1 and the HLA-B promoters in the HLA 
region in an independent cohort of treated celiac patients. Contrary to the reccomendations 
in force several years ago, current diagnosis protocols for CD do not include a control biopsy of patients on a 
gluten-free diet (GFD). Samples from asymptomatic, GFD-treated patients are very valuable given that genomic 
alterations are likely to reflect constitutive characteristics related to their genetic or epigenetic predisposition, 
Figure 4. Methylation and comethylation profiles of the HLA-DMR close to TAP1, in celiac epithelial (A) 
and immune (B) cells. The graphs at the top show the p values of the methylation differences between celiac 
and control cells in each CpG position. The black circle is the reference hit, and the color of the rest of the 
circles represents the Spearman correlation coefficient between the rest of the methylation values and the 
reference point, according to the color scale. The CG content is shown in red and the blue and the purple lines 
below represent the methylation levels in the control and the celiac patients, respectively. The squares in the 
correlogram at the bottom represent the pairwise correlation between CpG positions.
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that have been either inherited or acquired very early in childhood (before CD onset) or even in prenatal stages. 
In this context, DNA methylation was analyzed by NGS in bisulfite-treated, PCR-amplified fragments spanning 
the TAP1 and HLA-B DMRs in an independent cohort of GFD-treated CD patients and control individuals. Both 
DMRs are differentially methylated in DNA from complete biopsies of asymptomatic CD patients. In particular, 
we studied 6 CpG sites per locus and the differences between GFD-treated CD patients and controls were very 
significant for most of them (Fig. 5A).
According to our RNAseq results, TAP1 and PSMB9 were overexpressed in disease in all sample types (Fig. 5B) 
while the upregulation of HLA-B (and its overlapping pseudogene) was observed only in epithelial cells and in 
complete biopsies. These results are consistent with the fact that the HLA-B DMR is specific to the epithelial 
population. Additionally, both the TAP1-PSMB9 and the HLA-B-pseudogene pairs were regionally coexpressed 
across the entire dataset (Fig. 5C), suggesting a common regulatory mechanism.
Methylation quantitative trait loci and genotype-methylation interaction analyses in duode-
nal cell fractions. In order to ascertain whether methylation changes overlap sequence variants potentially 
explaining the phenotypic effect of some of the previously associated SNPs, methylation results were analyzed 
together with the Immunochip SNP genotypes39. We identified 1,423 and 1,457 mQTLs in epithelial and immune 
cells, respectively (FDR < 0.05), using previously defined criteria40 (Table S6). The mQTL-SNPs were more con-
sistent between cell types than the CpGs they regulated (Fig. S6). In fact, 46.5% of the SNPs participating to 
epithelial-mQTLs also took part in immune-mQTLs, while only 30.7% of the CpGs in epithelial-mQTLs were 
also present in the immune (Monte Carlo-corrected χ2 = 75.036, p < 9.99 × 1e-5). Additionally, there was an 
excess of promoter and TSS proximal regions in both epithelial and immune mQTL-SNPs compared to a ran-
dom list of Immunochip SNPs (T-test, p value < 0.001). The mQTL-SNPs identified in each particular cell type 
were enriched in enhancer elements that have been described in cell lines resembling each of the two cellular 
compartments, according to the Dragon ENhancers database (DENdb)41. Particularly, 21.7% of the SNPs par-
ticipating to the epithelia-specific mQTLs were located in epithelia-specific enhancers, compared to the 13.3% 
that mapped to non-specific enhancers; and 32.1% of the SNPs participating to the immune fraction-specific 
mQTLs were located in immune-enhancers, compared to the 12.4% that mapped to the non-specific ones (Monte 
Carlo-corrected χ2 = 52.114 and χ2 = 88.197, p < 9.99 × 1e-5, respectively).
In general, methylation levels of the CpGs regulated by the mQTLs did not differ between celiac patients 
and controls (Fig. 6), suggesting that the celiac methylation signature described above is independent from the 
mQTL-SNP genotypes. The only exception was the immune cell-specific DMP in the gene body of the HLA-DPB2 
pseudogene in the HLA region, that correlated with several SNPs (Fig. S7). Although there was a remarkable 
effect of the genotype in both the epithelial and immune cell fractions, the contribution to disease was restricted 
to the immune population, further supporting the idea of additional disease-predisposing factors other than 
genotype in the HLA region.
In order to asses the proportion of associated SNPs that are cell type-specific mQTLs, we searched for overlaps 
between the mQTL-SNPs and the most CD-associated SNPs (n = 7,144; p < 1e-4) from the Immunochip com-
pared to the less associated 7,144 variants. We found that 363/1423 and 311/1457 overlapped, resulting in very sig-
nificant enrichments for both epithelial (Monte Carlo random sampling-corrected χ2 = 226.97, p = 9.99 × 1e-05) 
and immune (Monte Carlo random sampling-corrected χ2 = 182.14, p = 9.99 × 1e-05) compartments, respec-
tively (Fig. 6). As expected, most of them mapped to the HLA region on chromosome 6 but there were some that 
mapped to other chromosomes, such as 15 CD-associated SNPs spanning 471,524 bp in the chemokine receptor 
cluster on chromosome 3 that were correlated to the methylation level of four different CpG sites in the epithelial 
cell fraction. Interestingly, 178 CD-associated SNPs participated in mQTLs with regulatory ability in the two 
cellular fractions, while the rest were cell type-specific. However, when those mQTLs mapping to the HLA region 
were excluded, only 13 SNPs that correlated with the methylation level of a single position (cg21209485) and were 
located in the gene body of MMEL1 on chromosome 1, appeared to be common to both cell types (Table S7).
Finally, we wanted to ascertain whether there is an enrichment of DMPs around CD-associated variants. For 
this purpose, we questioned whether CD-associated DMPs colocalize with CD-associated Immunochip loci18 and 
therefore could be at least partially explained by sequence variation. We could not find any epithelial nor immune 
cell-specific DMP within defined distances of CD-associated sites (bin sizes of 25, 50, 100 and 250 Kb around 
each SNP). In turn, we found increasing numbers of DMPs in the bins of our randomly picked Immunochip/
genome-wide SNP sets of the same size, also after Monte Carlo sampling correction, probably due to the broader 
representation of the genome. Moreover, when we took CD-associated regions as a whole instead of single posi-
tions, we found little, non-significant overlap with DMPs when compared to similar, non-associated regions of 
the Immunochip, consisting on two isolated CpGs in chromosomes 2 and 15 that were differentially methylated 
in the immune fraction.
Discussion
Here we present the first methylome study performed in duodenal mucosa samples from CD patients. We 
describe two profoundly different cell-type specific methylation profiles that are both characterized by a remark-
able loss of CGIs. However, the DMP overlap between the epithelial and immune compartments is limited and 
restricted to the HLA region, given that two out of the 4 epithelial cell-specific DMRs in that region are also 
detected in the immune compartment. It is hard to tell whether the signal in immune cells is real or a conse-
quence of the small (<10%) existing epithelial cell contamination of the immune fraction combined with a very 
pronounced differential methylation in the epithelium. Overall, the minimal overlap of differentially methylated 
hits between the two different cell populations and the negligible inflation of the raw methylation results suggest 
that the limited sample size can be circumvented, at least in part, by the cell separation strategy, in terms of the 
robustness of the results.
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On the other hand, expression analysis of the genes located in close proximity to the cell type-specific 
DMPs showed that in general, methylation alterations in the epithelial cell compartment have a greater func-
tional impact compared to those in the the immune fraction. Interestingly, many of the HLA genes affected by 
Figure 5. Validation of the TAP1 and HLA-B overlapping DMRs by direct bisulfite sequencing and expression 
analysis. (A) Genomic context and methylation patterns of CD patients (purple) and control individuals (blue) 
in each DMR. Methylation levels extracted from the methylation array are represented in the upper panel, while 
those obtained after direct bisulfite sequencing appear below and are referred to as “betas (validation)”. Green 
boxes represent CGIs. *, ** and *** represent p values < 0.05, 0.01 and 0.001 (unpaired T-test), respectively. 
(B) Expression patterns of the DMR-overlapping genes in the different cell compartments. Grey and black dots 
represent control and CD patients, respectively. (C) Coexpression of the regional gene-pairs.
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these methylation changes in the celiac epithelium were not only expressed in our dataset but also differentially 
expressed depending on the disease status. Nevertheless, it is important to note that even if expression altera-
tions in genes mapping close to the immune-specific DMPs were limited, they affected interesting genes such as 
IL15RA and ZFAT, that appeared to be overexpressed. The former is a well-known mediator of IL15 activity that 
is associated to CD42 and that can promote IEL survival in the disease, leading to the emergence of T cell clonal 
expansion43. In turn, ZFAT was originally identified as a candidate susceptibility gene for autoimmune thyroid 
disease and its deficiency in peripheral T cells results in a reduction in T cell counts with decreased expression of 
several interleukins44.
Regarding differential variation of methylation levels between disease groups, the results in the epithelial 
fraction are in line with previous findings that point to chronic inflammatory and precancerous stages as more 
prone to methylation variation35. In fact, the top two most significant DVMCs in epithelial cells mapped to an 
intergenic region several kilobases upstream of the promoter of NEDD1, a gene that has been related to gastric 
cancer45 and to a TSS-proximal intron in LIG4, a gene that harbors a recently discovered pathogenic variant 
responsible for IBD development46. In general, we found a borderline enrichment of IBD-related terms among 
the genes mapping close to the epithelial DVMCs. Additionally, the disease-associated changes in expression of 
the genes close to the top hits further support the idea of functionality of the methylation alterations observed. In 
contrast, the immune fraction shows the opposite trend when compared to the epithelial compartment. A plau-
sible explanation to the lower variation in the immue compartment of CD patients could be that there is a small 
number of expanded clones dominating the T-cell repertoire in the disease47 and thus reducing the heterogeneity 
of the immune cell population. Moreover, genes close to immune DVMCs were not enriched in any particular 
term and were generally not differentially expressed in CD, reinforcing the idea that loss of variation is more a 
consequence of clonal expansion rather than a functional feature. Overall, our results suggest that this approach 
could be an interesting tool for new target discovery in inflammatory conditions like CD.
The fact that most of the top DMRs identified both in and outside the HLA region exhibited loss of CGI 
boundaries, together with the finding that methylation levels of celiac epithelial cells are more variable than the 
same loci in controls, lead to the idea of celiac intestinal epithelia evoking precancerous stages of solid tumours, 
where there is a well described loss of boundaries between high and low methylation regions defined by CGIs36. 
Remarkably, several of the DMRs located outside the HLA region target genes related to the immune response, 
like NLRC5 and CAST. The former is an MHC class I regulator usually expressed in epithelial cells that has been 
shown to protect T lymphocytes from NK-cells in inflammatory conditions, and CAST plays a central role in 
the NFkB-mediated regulation of macrophage activation in inflammatory disorders of the gut48,49. Interestingly, 
NLRC5 shows a very significant hypomethylation of its CpG-dense promoter and it is overexpressed in CD.
An important result of this work is the observation of (at least partially) genotype-independent meth-
ylation changes in the HLA region, as shown by the fact that they are associated with the disease in a cell 
population-specific manner and are not under the control of any Immunochip-SNP in our mQTL analysis. 
Although a study on chronic HIV infection points towards differential methylation as a dynamic and pro-
gressive mechanism that can alter the expression patterns of HLA genes50, the majority of reports so far do 
not discard the effect of the strong linkage disequilibrium in the region or even describe those changes as fully 
Figure 6. mQTLs and their overlap with differential methylation and genetic association in CD. Manhattan 
plot of the p values of the putative cis-mQTLs identified in epithelial (top) and immune (bottom) cells. mQTL-
SNPs that correlated with individual DMPs are shown in pink (none of the DMP-correlated SNPs reached 
genome-wide significance in the putative cis-mQTLs in which they participated). In turn, SNPs associated to 
CD according to the Immunochip project1,39 are highlighted in yellow, and consequently, mark those mQTLs 
that overlap CD-associated variants, many of which are genome-wide significant.
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haplotype-dependent51. However, more recent works in the field have provided evidence supporting methyl-
ation as an independent layer of variation with functional effects in this complex genomic region, as can also 
be inferred from our results. This is the case of an interesting study on high-risk human papillomavirus, whose 
infection is able to repress HLA-E expression through methylation alteration52. Additionally, hypermethylation 
of the MHC locus RNF39 has been found to be associated with multiple sclerosis, accounting for a portion of risk 
independent from the well-stablished susceptibility conferred by HLA-DRB153.
Moreover, we were able to confirm the differential methylation of two different loci within the HLA region in 
an independent collection of complete biopsies coming from GFD-treated patients, particularly the TAP1 and 
HLA-B promoters. Very interestingly, expression results seem to be coherent with the cell type-specificity of the 
differential methylation around HLA-B. Altogether, these results are suggestive of a non-reversible epigenetic 
celiac signature that prevails after more than two years on GFD. Alternatively, these results could also suggest that 
certain methylation alterations are independent of gluten exposure and were acquired very early in life or even 
during fetal development. We propose these two elements and their overlapping genes as novel and independent 
candidates in the region. Particularly, TAP1 is an important HLA class-I surface peptide, and recent works have 
shown that impairement of this epigenetically regulated gene is responsible of the escape of cancer cells from the 
host’s immuno-surveillance54,55. In turn, the exacerbated expression of TAP1 observed in CD could indicate an 
anomalous boost of the adaptive immune system.
Finally, mQTL analysis revealed that at least a part of the celiac methylation signature is independent from the 
genotype. Since only Immunochip SNPs in cis have been used to build up the mQTL SNP-CpG pairs, we can-
not rule out that a number of differentially methylated hits are regulated by non-genotyped SNPs within the 
Immunochip regions or in trans with other variants elsewhere in the genome, although the frequency of these 
two cases is expected to be minimal. These findings oppose recent methylation and mQTL analyses in IBD by 
Ventham et al. in which they conclude that differential methylation is driven by genetic variation56. However, our 
results are still compatible with this idea given that first, the immunogenic insult and thus, the environmental 
factors driving disease are completely different in CD and IBD. Also, our sample size is more limited and conse-
quently we are probably not able to see the genetic variation-dependent methylation changes, due to the small 
differences in allele frequencies between patients and controls. In fact, there is a remarkable enrichment of SNPs 
participating to mQTLs in CD-associated variants that nevertheless regulate CpG positions that do not differ 
in disease. This was the case of the SNPs located in the gene body of MMEL1 on chromosome 1, that regulated 
a single CpG position in both cell populations, or of the variants spanning a 0.5 Mb region on chromosome 3 
that harbors several chemokine receptor genes, including CCR5, whose methylation levels have previously been 
associated to its expression57.
In conclusion, in CD, the two main cell populations of the duodenal mucosa present divergent methylation 
signatures that in the case of the epithelial fraction is reminiscent of precancerous solid tumors, harboring a 
greater variability and affecting several loci in the HLA region in a genotype-independent manner. Additionally, 
the association of several SNPs with CD could be explained by allele-specific methylation such as the case of the 
SNPs located in the MMEL1 locus. Finally, we can conclude that our results confirm previous studies58, according 
to which genome sequence variation has a broad effect on phenotype across cellular compartments, whereas epi-
genetic factors provide an additional layer of variation that is more tissue or even cell type-specific.
Availability of Data
Methylation and SNP genotype results are accessible in NCBI’s Gene Expression Omnibus (GEO) reposito-
ry through accession no. GSE84745 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84745), and 
RNAseq data have been deposited in NCBI’s Sequence Read Archive (SRA) with accession no. SRP077708 (http://
www.ncbi.nlm.nih.gov/sra/SRP077708).
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